drugset / Trial / NCT03373058
Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery
Phase 3
Unknown
310 enrolled
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Affiliated Cancer Hospital of Shantou University Medical College · collabBeijing Obstetrics and Gynecology Hospital · collabCancer Hospital of Guizhou Province · collabChinese PLA General Hospital · collabChongqing University Cancer Hospital · collabFirst Affiliated Hospital of Chongqing Medical University · collabFirst Affiliated Hospital, Sun Yat-Sen University · collabFourth Affiliated Hospital of Guangxi Medical University · collabHebei Medical University Fourth Hospital · collabHenan Cancer Hospital · collabHenan Provincial People's Hospital · collabObstetrics & Gynecology Hospital of Fudan University · collabPeking Union Medical College Hospital · collabPeking University Cancer Hospital & Institute · collabPeking University People's Hospital · collabRenJi Hospital · collabShandong Cancer Hospital and Institute · collabSouthern Medical University, China · collabSun Yat-Sen Memorial Hospital of Sun Yat-Sen University · collabThe Second Hospital of Hebei Medical University · collabThe Third Affiliated Hospital of Guangzhou Medical University · collabThe Third Xiangya Hospital of Central South University · collabThird Affiliated Hospital, Sun Yat-Sen University · collabTianjin Medical University Cancer Institute and Hospital · collabUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · collabWest China Second University Hospital · collabWuhan University · collabXiangya Hospital of Central South University · collabXinqiao Hospital of Chongqing · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This project is a multi-center, prospective, randomized controlled clinical observation the safety and efficacy of hyperthermic intraperitoneal chemotherapy in the treatment of advanced-stage epithelial ovarian cancer after cytoreductive surgery. Median recurrence-free survival is the primary end points of this project.
Timeline
- Start
- 2019-10-15
- Primary completion
- 2021-07-01
- Completion
- 2023-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | Other |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Other |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |
| Background | Carboplatin | Small molecule | — | Intravenous |